Navigation Links
Stem Cell Treatment may Prolong Lives of Children With Brittle Bone Disease

Researchers at Imperial College London have found that injections of stem cells during the gestation period may help prolong the lives of children with brittle bone disease , osteogenesis imperfecta (OI).

The genetic defect, detected in human foetuses by DNA testing or ultrasound, disrupts collagen production, leading to weak bones and stunted growth. Those with the condition suffer fractures while in the womb, and rarely survive beyond early adulthood.

Led by Nicholas Fisk of the college, the researchers studied mouse models of human type III osteogenesis imperfecta. They injected human foetal mesenchymal stem cells through the wall of the uterus into 14-day mouse foetuses.

It was found that at the age of 3 months, mice treated with stem cells had suffered just one-third of the long-bone fractures, as compared to their untreated counterparts. The experimental mice also had stronger bones and longer leg bones than the control subjects.

A report published in New Scientist magazine says that the treatment has already been tried in the US on three children with OI whilst still in the womb, with promising early results seen after the babies were born.

Fisk believes that though drugs exist to treat the disease, stem cell transplants may offer extra benefits.

The researcher, who presented the study at the annual meeting of the International Society for Stem Cell Research in Cairns, Australia, stresses that need for offering the treatment on a case-by-case basis.

However, other experts are of the opinion that clinical trials must be conducted before the treatment is offered to the public.


'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) ... Food & Beverage and Dietary Supplement market segments across ... and USA geographies east of the Rocky Mountains since 2012. Consistent performance ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering ... pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, ... step up to semi-automatic or fully-automatic case packing with a small footprint, rugged, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... serving the greater Venice, FL area, has initiated a fundraiser for a two ... accident just four days after Christmas. To support this beautiful child who is ...
(Date:2/8/2016)... ... , ... FileHold's document management software has been implemented by ... environment for FileHold software that is pay per user subscription-based and also does ... FileHold web services API. DocuSyst also advises clients on fully functioning back up ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Cardiovascular ... Summary GlobalData,s Medical Devices sector report, ... 2015" provides an overview of Cardiovascular Surgery Devices ... --> The report provides comprehensive ... of the products at various stages of development. ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology: